{"id":"abt-712","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4761843","moleculeType":"Unknown","molecularWeight":"704.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABT-712 targets FGFR1, a receptor tyrosine kinase involved in cell proliferation and survival in certain cancers. By inhibiting FGFR1 signaling, the drug aims to suppress tumor growth in malignancies driven by FGFR1 alterations or overexpression. This mechanism is particularly relevant in cancers with FGFR1 amplification or activating mutations.","oneSentence":"ABT-712 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cells dependent on FGFR1 activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:41.842Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lung cancer with FGFR1 alterations"},{"name":"Other solid tumors with FGFR1 dependency"}]},"trialDetails":[{"nctId":"NCT01333722","phase":"PHASE2","title":"Acute Pain Study Following Bunionectomy","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-04","conditions":"Pain","enrollment":100},{"nctId":"NCT01038609","phase":"PHASE2","title":"Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-12","conditions":"Pain","enrollment":250},{"nctId":"NCT00935311","phase":"PHASE2","title":"Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-06","conditions":"Pain","enrollment":122},{"nctId":"NCT00761150","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-09","conditions":"Chronic Low Back Pain","enrollment":308},{"nctId":"NCT00763321","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-09","conditions":"Chronic Low Back Pain","enrollment":287},{"nctId":"NCT01364922","phase":"PHASE2","title":"Phase 2 Chronic Low Back Pain Study","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-06","conditions":"Chronic Low Back Pain","enrollment":168},{"nctId":"NCT00298974","phase":"PHASE3","title":"A Study of Pain Relief in Osteoarthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-02","conditions":"Osteoarthritis","enrollment":873},{"nctId":"NCT00402792","phase":"PHASE3","title":"A Study of Extended-Release Hydrocodone/Acetaminophen (Vicodin CR®) in Subjects With Acute Pain Following Bunionectomy","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-12","conditions":"Pain","enrollment":150},{"nctId":"NCT00404183","phase":"PHASE2","title":"A Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR)and Placebo in Subjects With Osteoarthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-08","conditions":"Pain","enrollment":120},{"nctId":"NCT00404391","phase":"PHASE2","title":"A Study Comparing the Analgesic Activity of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Placebo in Subjects With Pain Following Bunionectomy Surgery","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-10","conditions":"Pain","enrollment":210},{"nctId":"NCT00195728","phase":"PHASE3","title":"Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain","status":"COMPLETED","sponsor":"Abbott","startDate":"2005-06","conditions":"Moderate to Severe Chronic, Non-malignant Pain","enrollment":431}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hydrocodone and acetaminophen extended-release","Hydrocodone bitartrate and acetaminophen extended-release","Hydrocodone/acetaminophen extended-release"],"phase":"phase_3","status":"active","brandName":"ABT-712","genericName":"ABT-712","companyName":"AbbVie (prior sponsor, Abbott)","companyId":"abbvie-prior-sponsor-abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABT-712 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cells dependent on FGFR1 activation. Used for Lung cancer with FGFR1 alterations, Other solid tumors with FGFR1 dependency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}